Latest filing published 18 Nov 2024 for Molecular Templates, Inc., €801k. Read the official filing
Across 13 buy signals with a settled T+90 return. Return basis: close on the day after publication.
This profile gathers the share dealings of Target N. Biotech V across 4 companies, led by Macrogenics Inc, Molecular Templates, Inc. and Radius Health, Inc. The record holds 31 filings, for trades running from 5 May 2021 to 14 November 2024.
Both buying and selling appear: 29 purchases worth €48.2M, against 1 sale worth €801k. Netting one side against the other leaves €47.4M of net buying. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Since January 2024: 1 purchase and 1 sale on the market.
In size, the median ticket on the buying side is €1.3M. Of 29 purchases, 2 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.
Most recently, on 18 November 2024, the filings show an open-market sale worth €801k in Molecular Templates, Inc. The most recent open-market purchase was published on 4 April 2024, 927 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 31 declarations